Email this article PATHOMORPHISM OF PROSTATE CANCER DURING HIGH-INTENSITY FOCUSED ULTRASOUND TREATMENT
- Authors: Fomkin R.N.1, Voronina E.S.1, Popkov V.M.1, Maslyakova G.N.1, Blyumberg B.I.1
-
Affiliations:
- V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia, Research Institute of Fundamental and Clinical Uronephrology, Saratov
- Issue: Vol 9, No 1 (2013)
- Pages: 55-61
- Section: PROSTATE CANCER
- Published: 30.03.2013
- URL: https://oncourology.abvpress.ru/oncur/article/view/176
- DOI: https://doi.org/10.17650/1726-9776-2013-9-1-55-61
- ID: 176
Cite item
Full Text
Abstract
The purpose of the study was to evaluate the efficiency of prostate cancer (PC) treatment using high-intensity focused ultrasound (HIFU) on the basis of morphometric and immunohistochemical (IHC) analyses of postoperative prostate biopsy specimens. The study subjects were 40 patients with localized and locally advanced PC. The postoperative morphological analysis was made on the basis of standard hematoxylineosin staining and morphometric and IHC studies using the following antibodies: PCNA, Bcl-2, AMACR, Е-cadherin, and ANDR (Dako). Pre- and post-HIFU therapy histological examination of the routinely hematoxylin-eosin-stained specimens showed that the therapeutic pathomorphism of the tumor corresponded to grades III and IV. It was established that the IHC study should be used as an additional crite-rion for the efficiency of PC therapy after HIFU ablation. In spite of positive clinical, laboratory, instrumental, and objective changes, the patients with high AMACR and Bcl-2 levels and decreased Е-cadherin expression may be considered as a group at risk for prolonged malignant growth or recurrent PC.
About the authors
R. N. Fomkin
V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia,Research Institute of Fundamental and Clinical Uronephrology, Saratov
Author for correspondence.
Email: rnfomkin@mail.ru
Russian Federation
E. S. Voronina
V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia,Research Institute of Fundamental and Clinical Uronephrology, Saratov
Email: rnfomkin@mail.ru
Russian Federation
V. M. Popkov
V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia,Research Institute of Fundamental and Clinical Uronephrology, Saratov
Email: rnfomkin@mail.ru
Russian Federation
G. N. Maslyakova
V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia,Research Institute of Fundamental and Clinical Uronephrology, Saratov
Email: rnfomkin@mail.ru
Russian Federation
B. I. Blyumberg
V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia,Research Institute of Fundamental and Clinical Uronephrology, Saratov
Email: rnfomkin@mail.ru
Russian Federation
References
Supplementary files
